Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Akebia Therapeutics (NASDAQ: AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced its participation in the upcoming H.C. Wainwright 3rd Annual BioConnect Investor Conference. The company's CEO John Butler and CCO Nik Grund will engage in a Fireside Chat on Tuesday, May 20, 2025, at 2:30 PM EDT at the Nasdaq Headquarters in New York City. Investors can access the presentation webcast through the "Investors" section of Akebia's website after the conference.
Akebia Therapeutics (NASDAQ: AKBA), un'azienda biofarmaceutica specializzata in trattamenti per le malattie renali, ha annunciato la sua partecipazione al prossimo H.C. Wainwright 3rd Annual BioConnect Investor Conference. Il CEO John Butler e il CCO Nik Grund terranno una Fireside Chat il martedì 20 maggio 2025 alle 14:30 EDT presso la sede del Nasdaq a New York City. Gli investitori potranno accedere alla trasmissione web della presentazione tramite la sezione "Investitori" del sito web di Akebia dopo la conferenza.
Akebia Therapeutics (NASDAQ: AKBA), una compañía biofarmacéutica centrada en tratamientos para enfermedades renales, ha anunciado su participación en la próxima H.C. Wainwright 3rd Annual BioConnect Investor Conference. El CEO John Butler y el CCO Nik Grund participarán en una Fireside Chat el martes 20 de mayo de 2025 a las 2:30 PM EDT en la sede de Nasdaq en la ciudad de Nueva York. Los inversores podrán acceder a la transmisión web de la presentación a través de la sección "Investors" en el sitio web de Akebia después de la conferencia.
Akebia Therapeutics (NASDAQ: AKBA)는 신장 질환 치료에 중점을 둔 바이오제약 회사로, 다가오는 H.C. Wainwright 3rd Annual BioConnect Investor Conference에 참여한다고 발표했습니다. 회사의 CEO John Butler와 CCO Nik Grund는 2025년 5월 20일 화요일 오후 2시 30분 EDT에 뉴욕시 나스닥 본사에서 Fireside Chat을 진행할 예정입니다. 투자자들은 회의 후 Akebia 웹사이트의 "Investors" 섹션을 통해 프레젠테이션 웹캐스트에 접속할 수 있습니다.
Akebia Therapeutics (NASDAQ : AKBA), une société biopharmaceutique spécialisée dans les traitements des maladies rénales, a annoncé sa participation à la prochaine H.C. Wainwright 3rd Annual BioConnect Investor Conference. Le PDG John Butler et le CCO Nik Grund participeront à une discussion informelle le mardi 20 mai 2025 à 14h30 EDT au siège du Nasdaq à New York. Les investisseurs pourront accéder à la retransmission de la présentation via la section "Investors" du site web d'Akebia après la conférence.
Akebia Therapeutics (NASDAQ: AKBA), ein biopharmazeutisches Unternehmen, das sich auf Nierenerkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden H.C. Wainwright 3rd Annual BioConnect Investor Conference angekündigt. Der CEO John Butler und der CCO Nik Grund werden am Dienstag, den 20. Mai 2025, um 14:30 Uhr EDT im Nasdaq-Hauptquartier in New York City an einem Fireside Chat teilnehmen. Investoren können die Präsentationsübertragung nach der Konferenz über den Bereich "Investors" auf der Akebia-Website abrufen.
- None.
- None.
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, and Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20 at 2:30 PM EDT.
A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conference.
The H.C. Wainwright BioConnect Investor Conference will take place on May 20, 2025, at the Nasdaq Headquarters in New York City.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
When is Akebia Therapeutics (AKBA) presenting at the H.C. Wainwright BioConnect Conference 2025?
Who will represent Akebia Therapeutics (AKBA) at the H.C. Wainwright Conference?
Where can investors watch Akebia Therapeutics' (AKBA) H.C. Wainwright Conference presentation?
Where is the H.C. Wainwright BioConnect Conference 2025 being held?
